Guardant Health Future Growth

Future criteria checks 1/6

Guardant Health is forecast to grow earnings and revenue by 20.7% and 17% per annum respectively. EPS is expected to grow by 26.4% per annum. Return on equity is forecast to be -41.3% in 3 years.

Key information

20.7%

Earnings growth rate

26.4%

EPS growth rate

Healthcare earnings growth16.3%
Revenue growth rate17.0%
Future return on equity-41.3%
Analyst coverage

Good

Last updated24 Apr 2024

Recent future growth updates

Recent updates

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Nov 20
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 26
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Sep 05
A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Aug 15
Is Guardant Health (NASDAQ:GH) A Risky Investment?

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

May 28
A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Apr 05
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Dec 28
Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Guardant: Saving Lives One Blood Test At A Time

Oct 16

Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Aug 15
Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Guardant Health's test gets FDA win for companion diagnostic to Enhertu's expanded use in lung cancer

Aug 12

Guardant Health: Recent Developments Signal More Upsides

Jul 31

Guardant Health: Pending Recession, May Hurt Cancer Care Demand

Jul 14

Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Apr 29
Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Guardant Health: Leaping Growth With Epic

Apr 14

Earnings and Revenue Growth Forecasts

NasdaqGS:GH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,001-333-212-11812
12/31/2025803-364-274-19321
12/31/2024664-399-318-25221
12/31/2023564-479-345-325N/A
9/30/2023536-432-363-337N/A
6/30/2023510-508-383-337N/A
3/31/2023482-665-418-355N/A
12/31/2022450-655-387-309N/A
9/30/2022431-606-388-296N/A
6/30/2022408-551-363-271N/A
3/31/2022391-419-309-221N/A
12/31/2021374-406-284-209N/A
9/30/2021344-409-249-191N/A
6/30/2021324-379-191-146N/A
3/31/2021298-336-143-107N/A
12/31/2020287-254-158-104N/A
9/30/2020271-185-129-75N/A
6/30/2020258-120-118-66N/A
3/31/2020245-77-102-56N/A
12/31/2019214-76-68-47N/A
9/30/2019184-76-60-43N/A
6/30/2019145-87-81-67N/A
3/31/2019111-97-89-70N/A
12/31/201891-85-92-72N/A
9/30/201878-75-85-64N/A
6/30/201867-84-87-68N/A
3/31/201857-83-77-65N/A
12/31/201750-89-81-72N/A
12/31/201625-46N/A-37N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GH's revenue (17% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: GH's revenue (17% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GH is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.